Examination of point mutations within the ABL kinase domain of Bcr-Abl fusion gene in Chinese patients with chronic myeloid leukemia who develop imatinib resistance

被引：0
|
作者：
Yang, Dongguang [1 ]
Zhang, Ri [2 ]
Gang, Honglin [3 ]
Gu, Jian [2 ]
Cen, Jian Nong [2 ]
机构：
[1] Jiang Su Su Bei People Hosp, Yangzhou Inst Hematol, Jiangsu, Peoples R China
[2] Suzhou Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China
[3] Yangzhou Univ, Dept Pharmacol, Jiangsu, Peoples R China
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4573.4573
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4573
引用
收藏
页码：214B / 215B
页数：2
相关论文
共 50 条
  • [21] Dynamics of BCR-ABL independent gene mutations in patients with chronic myeloid leukemia
    Obstfelder, E.
    Rinke, J.
    Schmidt, M.
    Schaefer, V.
    Waldau, A.
    Winkelmann, N.
    Hochhaus, A.
    Ernst, T.
    Oncology Research and Treatment, 2015, 38 : 188 - 189
  • [22] BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
    Sherbenou, Daniel W.
    Hantschel, Oliver
    Kaupe, Ines
    Willis, Stephanie
    Bumm, Thomas
    Turaga, Lalita P.
    Lange, Thoralf
    Dao, Kim-Hien
    Press, Richard D.
    Druker, Brian J.
    Superti-Furga, Giulio
    Deininger, Michael W.
    BLOOD, 2010, 116 (17) : 3278 - 3285
  • [23] Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL
    Yin, C
    Luthra, R
    Cortes, J
    Reeves, N
    Hayes, K
    Glassman, A
    Kantarjian, H
    Jones, D
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2004, 6 (04): : 416 - 416
  • [24] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
    Tikhonova, V.
    Misyurina, E.
    Kesaeva, L.
    Finashutina, Y.
    Krutov, A.
    Aksenova, E.
    Soldatova, I.
    Soldatkina, O.
    Ivanova, V.
    Novitskaya, N.
    Arshanskaya, E.
    Lazarev, I.
    Volkova, M.
    Pospelova, T.
    Konstantinova, T.
    Vysotskaya, L.
    Voloditcheva, E.
    Lapin, V.
    Davydkin, I.
    Turkina, A.
    Kolosheinova, T.
    Goryacheva, S.
    Chelysheva, E.
    Pristupa, A.
    Golubenko, R.
    Gavrilova, L.
    Volkova, S.
    Kuchma, G.
    Ovsyannikova, E.
    Zaklyakova, L.
    Kaplanov, K.
    Klitochenko, T.
    Misyurin, A.
    HAEMATOLOGICA, 2013, 98 : 548 - 548
  • [25] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
    Hasanova, Aypara
    Asadov, Chingiz
    Karimova, Nigar
    Shirinova, Aytan
    Aliyeva, Gunay
    Alimirzoyeva, Zohra
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [26] Clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    Nicolini, Franck
    HEMATOLOGIE, 2006, 12 (06): : 373 - 374
  • [27] Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
    Sun, Xiaoyan
    Cai, Xueting
    Yang, Jie
    Chen, Jiao
    Guo, Caixia
    Cao, Peng
    MOLECULES AND CELLS, 2016, 39 (12) : 869 - 876
  • [28] Consecutive but not isolated BCR-ABL transcript level rises are predictive of BCR-ABL kinase mutations in chronic myeloid leukaemia patients treated by imatinib
    Clark, RE
    Knight, K
    Lucas, CM
    Wang, L
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 52 - 52
  • [29] ANALYSIS OF BCR-ABL KINASE DOMAIN MUTATIONS IN HUNGARIAN PATIENTS WITH IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Nahajevszky, S.
    Barta, A.
    Lueff, S.
    Batai, A.
    Remenyi, P.
    Masszi, T.
    Fekete, S.
    Ujj, G.
    Tordai, A.
    Andrikovics, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 538 - 538
  • [30] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Sharma, Pratibha
    Kumar, Lalit
    Mohanty, Sujata
    Kochupillai, Vinod
    ANNALS OF HEMATOLOGY, 2010, 89 (03) : 241 - 247
12345